Mirador Therapeutics closed a $250 million Series B to advance precision medicines for immune diseases and signaled potential plans for an IPO later in the year, the company told Endpoints News. The financing will fuel discovery and clinical development as Mirador positions itself to compete in immunology. Investors and public‑market observers will watch program progression and regulatory milestones if the company moves toward an initial public offering.